Multimodal intervention
Multimodal intervention has been studied in 24 papers since 2016: 11 trials in people, 2 in animals, 7 reviews; 7 in the past year. The newest paper, Nov 6, 2026: “A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series”.
24 papers study it41 findingsUpdated
1 new paper in 30 daysSee all 24 papers on multimodal intervention
At a glance
Multimodal interventions improve physical function and quality of life in human trials, with independent labs finding these changes again. A trial in frail and prefrail older people with type 2 diabetes finds no clear mortality effect; another reports more serious adverse events. Some authors are affiliated with Ingenasa.
41 findings in 16 papers from 2017 to 2026, 2 of them since May 2026
Independent labs found the same change in people. 16 independent labs in 15 countries.
“IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26, P < 0.0001)”
None of its findings points the other way.
- 16 independent labs in 15 countries
- Funders: University of Zaragoza and others
- 5 of 41 findings with company ties
- Human trial11
- Animals2
Studies in people
See all 10 studies of multimodal intervention in people10 studies gave multimodal intervention to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases body weightWeight loss ranged from 7.7 to 17.1 kg down: Decreases lower-limb circumferences and subcutaneous adipose tissue thickness down: Decreases fasting glucoseDecreased in most cases | Treated cohort22–25 weeks | 5 peopleWomenLipedema and excess body weight; tirzepatide included in four participants | Journal of clinical medicine, Nov 6, 2026 |
up: Improves mobilityβ = -0.30, p < .05 up: Improves activities of daily livingβ = -8.40, p < .01 | Randomized trialsix months post-discharge | 589 people52% male79.57 ± 5.44 yearsGeriatric patients aged 70 years or older in an acute hospital setting with increased risk for delirium, mobility restrictions, functional decline, or re-hospitalization | Aging clinical and experimental research, Mar 8, 2026 |
no change: Has no effect on gait performance | Randomized trial12 weeks | 12 people72.6 ± 5.4 yearsOlder adults | BMC geriatrics, Nov 4, 2025 |
up: Improves quality of lifeOR 1.75 (95% CI 1.20, 2.54), p=0.004 down: Decreases disabilityOR 0.59 (95% CI 0.37, 0.93), p=0.023 | Randomized trial16 weeks | 843 peopleBoth≥ 70 yearsOlder adults; prefrail and frail with type 2 diabetes mellitus | Diabetes research and clinical practice, Jul 27, 2024 |
up: Raises the risk of serious adverse events+365% relative risk | Review of trialsmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months) | minimum age of 60 yearsParticipants in U.S.-based lifestyle clinical trials for cognitive health | Contemporary clinical trials communications, Feb 15, 2024 |
What did studies of multimodal intervention find?
33Studies of multimodal intervention measured 33 outcomes, among them inflammation, quality of life and physical function.
Inflammation
downin humans1downin mice1
2 studies
Inflammation
downin humans1downin mice1
Multimodal intervention decreases inflammation in humans.
Human trialthree monthsfemales
Multimodal intervention decreases inflammation in AD mice.
Animalsin AD mice
Quality of life
upin humans2OR 1.75
2 studies
Quality of life
upin humans2OR 1.75
Multimodal intervention improves quality of life in humans (β = 2.43, 95% CI [1.50, 3.35]).
Human trial18 months
Multimodal intervention improves quality of life in humans (prefrail and frail with type 2 diabetes mellitus) (OR 1.75 (95% CI 1.20, 2.54), p=0.004).
Human trialprefrail and frail with type 2 diabetes mellitus16 weeksn = 843
Physical function
upin humans2
2 studies
Physical function
upin humans2
Multimodal intervention improves physical function in humans (frail and pre-frail older people with type 2 diabetes mellitus) (0.85 points (95% CI, 0.44 to 1.26, P < 0.0001)).
Human trialfrail and pre-frail older people with type 2 diabetes mellitus12 monthsn = 964
Multimodal intervention improves physical function in humans during and immediate post-treatment.
Reviewduring and immediate post-treatment
Health care costs
downin humans2
2 studies
Health care costs
downin humans2
Multimodal intervention decreases health care costs in humans (frail and pre-frail people with type 2 diabetes, compared with usual care) (25% lower than usual care).
Human trialfrail and pre-frail people with type 2 diabetes, compared with usual careone year
Multimodal intervention decreases health care costs in humans (frail and pre-frail older people with type 2 diabetes mellitus) (mean saving of 428.02 EUR (2016) per patient per year).
Human trialfrail and pre-frail older people with type 2 diabetes mellitus12 months
Activities of daily living
upin humans1
1 study
Activities of daily living
upin humans1
Multimodal intervention improves activities of daily living in humans (β = -8.40, p < .01).
Human trialn = 589
Multimodal intervention improves activities of daily living in humans (hospitalized geriatric patients) (β = 7.98, p<.001).
Human trialhospitalized geriatric patientssix months post-dischargen = 589
Mobility
upin humans1
1 study
Mobility
upin humans1
Multimodal intervention improves mobility in humans (β = -0.30, p < .05).
Human trialn = 589
Multimodal intervention improves mobility in humans (hospitalized geriatric patients) (β = 0.70, p<.001).
Human trialhospitalized geriatric patientssix months post-dischargen = 589
Physical activity
upin humans1
1 study
Physical activity
upin humans1
Multimodal intervention increases physical activity in humans.
Human trial8 weeks
Multimodal intervention increases physical activity in humans (P value <0.05).
Human trial8 weeks
SF-36 scores
upin humans1
1 study
SF-36 scores
upin humans1
Multimodal intervention improves SF-36 scores in humans (tirzepatide phase with concurrent dietary, exercise, and supplementation interventions).
Human trialtirzepatide phase with concurrent dietary, exercise, and supplementation interventionstirzepatide 2.5–7.5 mg once weekly14–16 weeksfemalesn = 4
Fasting glucose
downin humans1
1 study
Fasting glucose
downin humans1
Multimodal intervention decreases fasting glucose in humans (lipedema and excess body weight) (Decreased in most cases).
Human triallipedema and excess body weight22–25 weeksfemalesn = 5
Lower-limb circumferences and subcutaneous adipose tissue thickness
downin humans1
1 study
Lower-limb circumferences and subcutaneous adipose tissue thickness
downin humans1
Multimodal intervention decreases lower-limb circumferences and subcutaneous adipose tissue thickness in humans (lipedema and excess body weight).
Human triallipedema and excess body weightlower-limb subcutaneous adipose tissue22–25 weeksfemalesn = 5
Body weight
downin humans1
1 study
Body weight
downin humans1
Multimodal intervention decreases body weight in humans (lipedema and excess body weight; tirzepatide included in four participants) (Weight loss ranged from 7.7 to 17.1 kg).
Human triallipedema and excess body weight; tirzepatide included in four participants22–25 weeksfemalesn = 5
Balance
no changein humans1
1 study
Balance
no changein humans1
Multimodal intervention showed no clear effect on balance in humans (β = 0.10, 95% CI [− 0.38, 0.58]).
Human trial18 months
Loneliness
downin humans1
1 study
Loneliness
downin humans1
Multimodal intervention decreases loneliness in humans (β = −1.25, 95% CI [− 1.99, − 0.52]).
Human trial18 months
Depression
downin humans1
1 study
Depression
downin humans1
Multimodal intervention decreases depression in humans (β = −1.32, 95% CI [− 1.81, − 0.82]).
Human trial18 months
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Multimodal intervention improves cognitive function in humans (β = 1.07, 95% CI [0.45, 1.70]).
Human trial18 months
All 33Fewer
What is multimodal intervention linked with?
1Studies link multimodal intervention with serious adverse events.
Serious adverse events
upin humans1+365% relative risk
1 study
Serious adverse events
upin humans1+365% relative risk
Multimodal intervention raises the risk of serious adverse events in humans (+365% relative risk).
Human trialmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months)
How this record changed
Summary written from the findings.